| Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia | Sarah de Crescenzo | 08/12/20 | San Francisco |
| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology | Frank Vinluan | 08/05/20 | Boston |
| Kymera Therapeutics Unveils IPO Pitch for Protein Degradation | Frank Vinluan | 07/31/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort | Sarah de Crescenzo | 07/29/20 | San Diego |
| Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test | Sarah de Crescenzo | 07/29/20 | National |
| Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma | Frank Vinluan | 07/24/20 | San Francisco |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Amgen Doubles Down on BeiGene Collaboration, Investing $421M More | Sarah de Crescenzo | 07/13/20 | San Francisco |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs | Sarah de Crescenzo | 07/09/20 | San Diego |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy | Sarah de Crescenzo | 07/02/20 | San Diego |
| Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs | Sarah de Crescenzo | 07/01/20 | San Francisco |
| Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs | Sarah de Crescenzo | 06/25/20 | Boston |
| Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx | Frank Vinluan | 06/22/20 | San Francisco |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug | Frank Vinluan | 06/18/20 | Seattle |
| Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies | Frank Vinluan | 06/17/20 | San Francisco |
| Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer | Sarah de Crescenzo | 06/17/20 | San Diego |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel | Frank Vinluan | 06/16/20 | Philadelphia |
| Merck’s Keytruda Fails Pivotal Bladder Cancer Study, Sinks First-Line Hopes | Frank Vinluan | 06/10/20 | New York |
| Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug | Frank Vinluan | 06/05/20 | New York |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline | Frank Vinluan | 06/04/20 | Boston |
| Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins | Sarah de Crescenzo | 06/04/20 | Boston |
| Grail Plants a Seed in RTP, Pledges $100M Investment in New Site | Frank Vinluan | 06/02/20 | Raleigh Durham |
| Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech | Frank Vinluan | 06/02/20 | Seattle |
